Back to Agenda
Session 6: Global Regulatory Affairs
Session Chair(s)
Cristiana Mayer, DrSc, PhD
Head of Biostatistics
Johnson & Johnson Vision, United States
Amy Xia, PhD
Vice President, Center for Design and Analysis
Amgen Inc., United States
John Scott, PhD, MA
Division Director, Office of Biostatistics, CBER
FDA, United States
This session will consist of two presentations from EMA, and PMDA followed by a panel from FDA, EMA, and PMDA to discuss their perspectives on use of complex innovative designs (CID). We will highlight the regulatory principles, current thinking and activities related to utilization and evaluation of innovative designs in various regulatory agencies. Challenges, opportunities and best practices in applying CID will be described. Furthermore, we will discuss key aspects on how to interact with regulatory agencies in different regions on global trials with CID for the purpose of global registration.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Get familiar with regulatory guidance documents and activities related to CID in different regions
- Articulate the regulatory principles of CID
- Describe challenges, opportunities and best practices in applying CID
- Discuss considerations for the planning and implementation of clinical trials with CID and the interactions between sponsors and regulatory agencies
Speaker(s)
Speaker
John Scott, PhD, MA
FDA, United States
Division Director, Office of Biostatistics, CBER
Speaker
Frank Petavy, MS
European Medicines Agency, Netherlands
Head of Methodology
Speaker
Yuki Ando, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Principal Senior Scientist for Biostatistics
Have an account?